Breaking Down Teijin Limited Financial Health: Key Insights for Investors

Peeling back the numbers on Teijin Limited (3401.T) reveals a company at a crossroads: consolidated revenue of JPY 1,005.5 billion for FY ending Mar 31, 2025 (TTM Sep 30, 2025: JPY 949.01 billion, down 8.20% YoY) and a sharp quarterly drop to JPY 207.93 billion (‑17.54% YoY), while profitability paints mixed signals-FY net income of JPY 23.16 billion versus a TTM net loss of JPY ‑78.04 billion and an operating margin of ‑7.71% after a JPY 28 billion impairment on diabetes treatments; balance-sheet figures show total assets of JPY 1.15 trillion, liabilities of JPY 709.01 billion (debt‑to‑equity ~1.63), cash and short‑term investments up 52.88% to JPY 215.60 billion but negative free cash flow of JPY ‑14.59 billion for the quarter, and valuation metrics that include an enterprise value of JPY 518.31 billion, market cap around JPY 249.42 billion, a TTM P/E of 9.28 and P/B near 0.60-read on to unpack how these figures, risk items (including a ~JPY 11 billion subsidiary sale loss) and strategic moves in tissue engineering and aramid restructuring could reshape investor prospects

Teijin Limited (3401.T) - Revenue Analysis

• FY ending Mar 31, 2025 consolidated revenue: JPY 1,005.5 billion (-2.64% YoY)
• TTM revenue (as of Sep 30, 2025): JPY 949.01 billion (-8.20% YoY)
• Q1 (ending Sep 30, 2025) revenue: JPY 207.93 billion (-17.54% YoY)
• Revenue per employee: ≈ JPY 46.80 million (20,279 employees)
• Market capitalization: JPY 253.86 billion; Price-to-Sales (P/S): 0.27

• Primary drivers of revenue weakness: intensified competition across materials and fibers businesses; expected government-led drug price revisions reducing pharmaceutical sales.
• Operational implication: lower revenue per employee trend versus prior periods, necessitating either margin recovery or volume stabilization.
• Valuation note: P/S of 0.27 reflects market skepticism relative to sales scale (market cap JPY 253.86 billion vs. TTM revenue JPY 949.01 billion).

Teijin Limited (3401.T) - Profitability Metrics

• Fiscal year (FY) net income (year ended March 31, 2025): JPY 23.16 billion
• Trailing twelve months (TTM) net income as of June 30, 2025: JPY -78.04 billion (loss)
• Operating margin (FY ended March 31, 2025): -7.71%
• Return on equity (ROE): 5.54%
• Return on assets (ROA): 2.03%
• Earnings per share (EPS) for FY ended March 31, 2025: JPY 147.15
• Impairment losses recorded in Q4 FY2025 related to diabetes treatments in Japan: JPY 28 billion

• Negative operating margin (-7.71%) signals pressure on core operations despite a small positive FY net income; impairment charges materially affected profitability.
• The stark divergence between FY net income (JPY 23.16B) and TTM net loss (JPY -78.04B) highlights recent large, non-recurring hits (notably the JPY 28B impairment) and possibly continuing operational drag.
• ROE of 5.54% and ROA of 2.03% indicate moderate capital and asset efficiency but are strained by recent losses-investors should monitor whether returns recover as one-offs are digested.
• EPS of JPY 147.15 for FY2025 masks the subsequent TTM deterioration; watch future EPS guidance and reserve/impairment disclosures.

Teijin Limited (3401.T) Debt vs. Equity Structure

• High leverage: D/E ≈ 1.63 indicates reliance on debt financing relative to shareholders' equity.
• Market discount to book: P/B = 0.60 suggests the market capitalization is meaningfully below recorded equity.
• Enterprise value vs. market cap: EV (JPY 518.31B) > market cap (JPY 249.42B) due to the inclusion of debt in EV.

• Implication for equity holders: P/B < 1 can signal undervaluation but may also reflect operational or sector risks priced in by the market.
• Implication for creditors: D/E ~1.63 implies moderate-to-high leverage-creditors should monitor interest coverage and cash flow adequacy.
• Capital allocation considerations: management can reduce leverage via asset sales, equity issuance, or retained earnings; small YoY share increase (0.10%) shows limited dilution.

Teijin Limited (3401.T) - Liquidity and Solvency

• Cash & short-term investments: JPY 215.60 billion (up 52.88% YoY as of June 30, 2025).
• Net income (Q ended Jun 30, 2025): JPY -740 million (down 116.63% YoY).
• Operating cash flow (Q ended Jun 30, 2025): JPY 16.62 billion (up 92.58% YoY).
• Free cash flow (Q ended Jun 30, 2025): JPY -14.59 billion (negative).
• Current ratio and quick ratio: not explicitly disclosed; inferred to be adequate given the strong cash balance and receivables, though inventory impact is unspecified.

Teijin Limited (3401.T) Valuation Analysis

• Trailing twelve months (TTM) price-to-earnings (P/E): 9.28 - indicates historically low price relative to recent earnings.
• Forward P/E: 18.77 - implies the market expects earnings improvement or reflects near-term premium pricing.
• Price-to-sales (P/S): 0.26 - valuation is modest relative to revenue.
• Price-to-book (P/B): 0.65 - stock trades below book value, suggesting potential undervaluation or balance-sheet risk priced in.
• PEG ratio: 11.73 - very high, indicating the share price is high relative to expected earnings growth.
• Earnings yield (FY ending Mar 31, 2025): 11.23% - an attractive yield relative to many equities and fixed-income alternatives.

• Relative valuation takeaway: Low TTM P/E, P/S, and P/B suggest current earnings and asset coverage are cheap, but the forward P/E and PEG signal the market prices in higher future expectations or growth uncertainty.
• Capital structure and EV: Enterprise value (JPY 518.31B) roughly double market cap (JPY 249.42B), indicating meaningful net debt or other non‑equity claims that affect takeover or replacement-value assessments.
• Investor focus: Compare the 11.23% earnings yield versus cost of capital and bond yields in Japan; assess whether the high PEG is due to low growth projections or anomalous near-term earnings base effects.

Teijin Limited (3401.T) Risk Factors

• Significant one-off losses: Teijin recorded an impairment loss of JPY 28.0 billion related to its diabetes treatments in Japan in Q4 of the fiscal year ended March 31, 2025, reducing asset values and signaling underperformance in that business line.
• Upcoming disposal loss: The company incurred an approximate JPY 11.0 billion loss on the sale of subsidiary shares, to be recognized in Q2 of the fiscal year ending March 31, 2026, which will further depress reported earnings and cash from investing activities for that period.
• Negative operating profitability: Operating margin for FY ended March 31, 2025, was -7.71%, indicating core operations are currently loss-making before financing and tax items.
• Material net loss on a trailing basis: Net income for the trailing twelve months as of June 30, 2025, is JPY -78.04 billion, reflecting sustained aggregate losses that may strain retained earnings and capital buffers.
• High leverage: A debt-to-equity ratio of approximately 1.63 denotes elevated indebtedness relative to shareholders' equity, increasing interest burden sensitivity and refinancing risk in tighter credit conditions.
• Market size and equity base: Market capitalization stands at JPY 249.42 billion with 192.90 million shares outstanding, which frames valuation and potential dilution considerations for equity investors.

Teijin Limited (3401.T) - Growth Opportunities

• Partnership to strengthen research and manufacturing capabilities in advanced tissue engineering products, reinforcing Teijin's push into higher-margin healthcare and regenerative-medicine markets.
• Transfer of shares in aramid paper joint ventures to DuPont as DuPont exits aramid operations - a move that streamlines Teijin's portfolio and reallocates resources toward prioritized growth segments.
• Market-capitalization scale: JPY 249.42 billion with 192.90 million shares outstanding, indicating investor valuation and per-share resource base for future investments or buybacks.

• Healthcare & regenerative medicine: leverage the new tissue-engineering partnership to build recurring-revenue product lines and upstream manufacturing capabilities.
• High-performance fibers & composites: consolidate wins from the aramid restructuring to re-invest in carbon-fiber, PEEK, and other advanced-materials R&D.
• Global manufacturing footprint optimization: redeploy capital from divested/streamlined units into regions with high growth potential (North America, EU, APAC healthcare hubs).
• Balance-sheet management: with JPY 436.08 billion equity vs. JPY 709.01 billion liabilities, prioritize deleveraging or selective M&A funded by cash flow to improve leverage ratios and credit metrics.